{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-182567","form_type":"8-K","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2024-07-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.784547+00:00","generated_at":"2026-05-31T18:19:13.848049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Owens & Minor reports preliminary Q2 GAAP net loss $0.42-0.46/share, adj. EPS $0.32-$0.36; reaffirms FY guidance","bullets":["Revenue $2,651-$2,671M; GAAP net loss per share $(0.42)-$(0.46); adjusted EPS $0.32-$0.36.","One-time income tax charge of $17M ($0.22/share) from transfer pricing dispute; expected cash payment $30-$35M in H2 2024.","Full-year 2024 outlook reaffirmed: revenue $10.5-$10.9B, adj. EBITDA $550-$590M, adj. EPS $1.40-$1.70.","Adjusted EBITDA $123-$127M; operating cash flow $111-$116M; net debt reduction $68-$71M.","Full Q2 results to be released on August 2, 2024, before NYSE open."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-182567","json":"https://secwatch.observer/filing/0001193125-24-182567.json","markdown":"https://secwatch.observer/filing/0001193125-24-182567.md","text":"https://secwatch.observer/filing/0001193125-24-182567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000119312524182567/0001193125-24-182567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000119312524182567/d857019d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T18:19:13.848049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}